ABSTRACT NUMBER: ESOC2026LB159 PREDICTORS OF RECURRENT ISCHAEMIC STROKE IN PATIENTS WITH NON-CARDIOEMBOLIC ISCHAEMIC STROKE: INSIGHTS FROM THE OCEANIC-STROKE RANDOMISED TRIAL OF ASUNDEXIAN FOR SECONDARY STROKE PREVENTION

Abstract Background and aims In OCEANIC-STROKE, asundexian 50 mg once daily added to antiplatelet therapy reduced ischaemic stroke (IS) compared with placebo (cause-specific hazard ratio [HR], 0.74; 95% confidence interval [CI]: 0.65–0.84). We examined predictors of recurrent IS and whether these modified the treatment effect of asundexian. Methods We randomized 12,327 participants within 72 h of acute non-cardioembolic IS or high-risk TIA to asundexian or placebo. The primary efficacy endpoint was time to first IS. Multivariable regression identified baseline predictors of recurrent IS in patients with qualifying IS (n=11,677) at study entry. Potential interactions between these variables and the treatment effect of asundexian for the primary efficacy endpoint were explored using the intention-to-treat principle. Results Over a median follow-up of 1.6 years, 843 IS occurred; the annualised rate of IS was 5.1%. Assignment to asundexian was independently associated with lower risk of recurrent IS (HR, 0.73; 95% CI: 0.64–0.84). Older age (HR [per year]; 1.01; 1.00–1.02), Black (1.67; 1.14–2.45) and Other race (1.68; 1.22–2.32) versus White race, history of diabetes (1.39; 1.21–1.60), previous stroke or TIA (2.05; 1.77–2.36), index IS attributed to large-artery atherosclerosis (1.41; 1.23–1.62) and medical history of atherosclerosis (1.26; 1.09–1.46) were associated with higher risk of recurrent IS. No heterogeneity in the treatment effect of asundexian was observed across these variables (Figure). Conclusions Baseline characteristics identify patients with acute non-cardioembolic IS at increased risk of IS recurrence. Asundexian consistently reduced recurrent IS without evidence of treatment-effect heterogeneity across these higher-risk subgroups of patients. Conflict of interest Figure 1 - belongs to Results

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.1896
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026LB159 PREDICTORS OF RECURRENT ISCHAEMIC STROKE IN PATIENTS WITH NON-CARDIOEMBOLIC ISCHAEMIC STROKE: INSIGHTS FROM THE OCEANIC-STROKE RANDOMISED TRIAL OF ASUNDEXIAN FOR SECONDARY STROKE PREVENTION

Eva Muehlhofer, Peter Turčáni, Serefnur Ozturk, Karleen Schulze et al.
European Stroke Journal
Acute Ischemic Stroke Management
article

ABSTRACT NUMBER: ESOC2026LB159 PREDICTORS OF RECURRENT ISCHAEMIC STROKE IN PATIENTS WITH NON-CARDIOEMBOLIC ISCHAEMIC STROKE: INSIGHTS FROM THE OCEANIC-STROKE RANDOMISED TRIAL OF ASUNDEXIAN FOR SECONDARY STROKE PREVENTION

Eva Muehlhofer, Peter Turčáni, Serefnur Ozturk, Karleen Schulze, Hanne Christensen, Mukul Sharma, Ronen R Leker, Jose Férro, Ashkan Shoamanesh
article en

Abstract

Abstract Background and aims In OCEANIC-STROKE, asundexian 50 mg once daily added to antiplatelet therapy reduced ischaemic stroke (IS) compared with placebo (cause-specific hazard ratio [HR], 0.74; 95% confidence interval [CI]: 0.65–0.84). We examined predictors of recurrent IS and whether these modified the treatment effect of asundexian. Methods We randomized 12,327 participants within 72 h of acute non-cardioembolic IS or high-risk TIA to asundexian or placebo. The primary efficacy endpoint was time to first IS. Multivariable regression identified baseline predictors of recurrent IS in patients with qualifying IS (n=11,677) at study entry. Potential interactions between these variables and the treatment effect of asundexian for the primary efficacy endpoint were explored using the intention-to-treat principle. Results Over a median follow-up of 1.6 years, 843 IS occurred; the annualised rate of IS was 5.1%. Assignment to asundexian was independently associated with lower risk of recurrent IS (HR, 0.73; 95% CI: 0.64–0.84). Older age (HR [per year]; 1.01; 1.00–1.02), Black (1.67; 1.14–2.45) and Other race (1.68; 1.22–2.32) versus White race, history of diabetes (1.39; 1.21–1.60), previous stroke or TIA (2.05; 1.77–2.36), index IS attributed to large-artery atherosclerosis (1.41; 1.23–1.62) and medical history of atherosclerosis (1.26; 1.09–1.46) were associated with higher risk of recurrent IS. No heterogeneity in the treatment effect of asundexian was observed across these variables (Figure). Conclusions Baseline characteristics identify patients with acute non-cardioembolic IS at increased risk of IS recurrence. Asundexian consistently reduced recurrent IS without evidence of treatment-effect heterogeneity across these higher-risk subgroups of patients. Conflict of interest Figure 1 - belongs to Results

European Stroke JournalVol. 11(Supplement_1)
Selçuk University (TR), Hadassah Medical Center (IL), Frederiksberg Hospital (DK), Population Health Research Institute (CA), Hospital de Santa Maria (PT), Bayer (Germany) (DE), Comenius University Bratislava (SK)
Life below water
Openalex Percentile: Top 10%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.